Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England
Despite currently available care, patients with SCD with recurrent VOCs in England have increased mortality, substantial clinical complications, and significant HCRU driven by VOCs and hospitalizations. Elevated mortality and clinical complications in patients with SCD with recurrent VOCs highlight the need for novel therapies in this space.
Authors
- Nanxin Li (ORCID: https://orcid.org/0009-0006-4412-0997)
- Sarah C. Conner (ORCID: https://orcid.org/0000-0002-0929-9948)
- Jo Howard (ORCID: https://orcid.org/0000-0001-9363-6531)
- Steven Fleming (ORCID: https://orcid.org/0000-0002-6242-8083)
- Farrukh Shah (ORCID: https://orcid.org/0000-0001-5975-1309)
- Fiona C. Ingleby (ORCID: https://orcid.org/0000-0003-1800-2015)
- Nelly F Ly (ORCID: https://orcid.org/0000-0002-7527-110X)
- Chuka Udeze
Institutions
- Whittington Hospital (GB)
- IQVIA (United Kingdom) (GB)
- University College London (GB)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Clinical Therapeutics
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1016/j.clinthera.2024.09.023
- Citations
- 6
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.63
Funders
- Vertex Pharmaceuticals